Title: Cascade of care, awareness and treatment of Chronic Hepatitis B in Malaysia- findings from a community-based screening campaign.

Authors:

¹Lim ZZ, ¹Teo JS, ¹Tan AC, ²Tan Soek Siam, ³Rosmawati Mohamed, ³Goh KL, ⁴Lee YY, ⁵Lai WH, ¹Lim TO

¹Hepatitis Free Pahang Malaysia, ²Hospital Selayang, ³University Malaya Medical Centre, ⁴University Sains Malaysia, ⁵Clinical Research Centre Ministry of Health Malaysia.

Corresponding author:

Dr Lim TO, Hepatitis Free Pahang Malaysia

Email: limteckonn@gmail.com

Summary

Introduction

In 2016 the World Health Organization (WHO) had adopted a global strategy to eliminate Hepatitis B (HBV) by 2030 through five core interventions, the first four were preventive while the fifth is the “cascade of care”, the continuum of services that persons with chronic HBV should receive as they progress from screening to diagnosis to treatment to chronic care. We determined the prevalence of the awareness and treatment of chronic HBV in Malaysia based on a large sample data from a screening campaign.

Methods

A total of 10,436 subjects participated in the HBV screening campaign organized by the Hepatitis Free Pahang Malaysia (HFPM) in 2018 and 2019. All screen-positive subjects were recalled to undergo laboratory-based HBsAg and HBV DNA tests. Patients with confirmed chronic HBV were referred to local health services, while continued being monitored by HFPM.

Results

We estimated 13.1% of Malaysian adults aged 20 or older with chronic HBV were aware of their HBV status, and of those only 0.7% had received prior anti-viral treatment, but among those with baseline HBV DNA level >20,000 IU/ml, 15.6% were subsequently treated. Tenofovir disoproxil fumarate was the only medicine used on all treated patients. The linkage to care post-screening was broken in substantial number of patients, only 108 (54%) subjects had returned to have their HBV DNA measured and only 115 (58%) patients had subsequently sought care and were on still follow-up.

Conclusion

Few Malaysian adults with HBV were aware of their infection and even less received anti-viral therapy. Concerted public health efforts are urgently needed to improve HBV screening and care cascade in order to meet WHO’s targets for HBV elimination.

Keywords

Cascade of care, Awareness, Treatment, Hepatitis B, Malaysia

Introduction

Chronic hepatitis B (HBV) is endemic in the Asia pacific region [1] including in Malaysia. A recent survey [2] estimated a prevalence of 1.2% amongst multi-ethnic Malaysian population; the disease is particularly common among Chinese with a prevalence of 2.2%. Untreated patients with HBV will progress rapidly to cirrhosis and hepatocellular carcinoma (HCC) [3]. HBV is the most common risk factor for liver cancer and accounted for more than half of all liver cancer worldwide [4]. According to the Global Burden of Disease Study 2010 [5], liver cirrhosis accounted for 42,000 years of life lost (YLLs) or 1.1% of total YLLs; it ranks ninth among the top ten major disease burden in Malaysia. Similarly, HCC is not only common (5th commonest cancer), it is also the most deadly cancer in Malaysia [6], even more so than cancer of the pancreas (Table 1). Five-year patient survival with liver cancer is only 2%, this is corroborated by the only published study on HCC survival in Malaysia which reported a median survival of only 1.9 months [7]. Fortunately, therapeutic advances have rendered chronic HBV more treatable. These anti-viral therapies not only retard progression to cirrhosis, and improve survival among patients with HCC, but also cost-effective [4,8,9].

Table 1: Top Ten most deadly cancers in Malaysia, data from Globocan 2018[6]

#	Cancer	Crude Incidence per 100,000 population	Crude Mortality per 100,000 population	5 year survival probability
1.	Liver	6.1	6.0	0.02
2.	Pancreas	3.0	2.9	0.03
3.	Brain, nervous system	2.4	2.2	0.08
4.	Oesophagus	1.3	1.2	0.08
5.	Lung	14.6	12.7	0.13
6.	Stomach	5.0	4.1	0.18
7.	Gallbladder	1.1	0.9	0.19
8.	Leukaemia	5.4	4.3	0.20
9.	Ovary	8.2	5.2	0.37
10	Nasopharynx	6.5	3.7	0.43
0	All cancers	136.8	82.4	0.40

In 2016 the World Health Organization adopted a global strategy to eliminate HBV and HCV by 2030 [10]. The “cascade of care”, the continuum of services that persons with chronic HBV should receive as they progress from screening to diagnosis to treatment to chronic care, is one of five core interventions to eliminate HBV. However most people with chronic HBV remain undiagnosed and untreated globally; WHO estimated only 9% of people were aware of their chronic HBV, and of those only 8% received anti-viral therapy [11].

In this study, we provide estimates of the prevalence of HBV awareness and treatment in Malaysia based on a large sample data derived from community-based screening campaigns in 2018 and 2019 organized by Hepatitis Free Pahang Malaysia (HFPM) [12]. HFPM is a Malaysia-based Non-Governmental Organization (NGO) established in 2017. The mission of HFPM is to mobilize local community to raise awareness about HBV and HCV, to provide free public screening services and to improve access to costly treatments for chronic HCV and HBV. The campaigns are entirely funded by

charity and is conducted through partners in each localities or districts in Pahang and other States.

Methods

Study population

Study sample for this study are people who attended the HFPM's screening campaigns in 2018 and 2019. In inviting local partners to jointly conduct these campaigns, we deliberately excluded NGOs or healthcare providers whose members or clientele potentially include persons at high risk of HBV or HCV (such as transgender, sex-worker or former prisoner/drug-user welfare groups, fisherman or other high risk trade associations, HIV/STD or opioid substitution clinics, drug rehabilitation centre or prison hospitals). The Ministry of Health's (MOH) Medical and Research Ethics Committee approved the study and all subjects gave informed consent.

Registration, screening and confirmatory tests.

All participants of the screening campaign were required to register online (see https://hepatitisfreemia.org.my/page.jsp?pageId=pPatientReg_Disclaimer&type=Screening). The online data system helped to support the conduct of the screening, to manage screen-positive subjects for subsequent testing and counselling, to facilitate reporting of results through short messaging service and to help capture the data for this study.

We used a low-cost point-of-care HBsAg test (POCT, AllTest Biotech Hangzhou China) to screen for HBV. The POCT have previously been validated [13]. The tests were conducted by trained nurses. The procedure was explained and verbal permission obtained from the participant prior to the testing. All screen-positive subjects were subsequently recalled to undergo testing, which were lab based serology and HBV DNA tests. Another trained nurse would counsel patients confirmed to have chronic HBV on infection transmission, risk of liver disease progression, need for monitoring and treatment. All HBsAg+ individuals were referred to the local health service for further care if they were not already receiving care. All individuals were also offered free monitoring of their HBV DNA levels by HFPM.

Definitions

For the purpose data analysis,

- Subjects with chronic HBV were defined as those who were tested positive on the POCT and subsequently re-tested positive by lab based HBsAg test.
- Awareness of HBV status in subjects with chronic HBV was defined as answering "yes" to the nurse-administered question: "Have you ever been tested or told by a doctor that you have hepatitis B?", and corroborated by enquiry on the circumstances leading to testing (eg pre-employment, insurance, routine health check, the name of healthcare provider providing care, if any).
- Prior treatment of chronic HBV was defined as answering "yes" to the nurse-administered question: "Were you or are you currently on anti-viral treatment prescribed by a doctor?", and corroborated by enquiry on the name of prescribing provider, the name of the medicine(s) and on previous HBV DNA test results.

- Prospective treatment of chronic HBV was defined as patients with HBV DNA >20,000 IU/ml [14,15] measured at baseline when they were recalled to undergo confirmatory testing and who subsequently received anti-viral treatment.

Data and Statistical analysis

The sample size for this study was based on expected chronic HBV prevalence of 2.0% and precision of the estimate as measured by its 95% exact binomial confidence intervals (CI). For a sample size of 10,000, a prevalence of 2.0% can be estimated with a 95% CI of 1.7 to 2.3, which is deemed sufficiently precise.

Participants in the screening campaign composed of a convenience sample which is not representative of the general population (female, older subjects, Chinese and Pahang residents were over-represented compare to the population). To estimate the population prevalence, post stratification [16] was used to adjust the sample totals to known population totals for age, gender and ethnicity based on the Population And Housing Census of Malaysia in 2010.

Results

A total of 10,436 subjects participated in HBV screening campaigns in 2018 and 2019, of whom 200 were identified to have chronic HBV. Table 2 shows the characteristics of these 200 subjects. Their mean age was 52 years, with equal number of males and females, and predominantly of Chinese ethnicity (91%). Perinatal transmission is the commonest risk factor as indicated by maternal (30%) or sibling (52%) history of HBV, living with others who had HBV (55%). A high proportion of patients reported the use of acupuncture or cupping (bekam) treatment (42%), tattoo or other body piercing (25%) and needle-stick injury (38%) as possible risk factors for HBV. Drug use, transgender or sex with other men were under-reported, as expected as these are considered criminal behaviors in Malaysia and the questionnaire administration was not anonymized.

Of the 200 subjects with chronic HBV, only 2 (1%) had prior anti-viral treatment. Post-screening, 108 of the 200 subjects had had their HBV DNA measured. Their median HBV DNA level was 10,804 IU/ml, 37% had levels below 2,000 IU/ml while 41% had levels above 20,000 IU/ml. Only 115 (58%) individuals had subsequently sought care and were on follow-up, but only 6 (3%) received anti-viral treatment.

The prevalence of awareness and anti-viral treatment among Malaysian adults age 20 or older with chronic HBV was 13.1% and 0.7% respectively (Table 3). Of those with baseline HBV DNA >20,000 IU/ml, 15.6% had subsequently received anti-viral treatment. All were treated with Tenofovir disoproxil fumarate only.

Table 2: Characteristics of Chronic HBV subjects detected among 10,436 subjects screened in 2018-2019

Characteristics	Result
Total number of subjects with Chronic HBV	200
Age, year	
Mean (SD)	52(12)
20-30 years	3(2)
30-39 years	36(18)
40-49 years	57(28)

	50-59 years	46(23)
	>=60 years	58(29)
Gender, No (%)		
	Male	103(51)
	Female	97(49)
Ethnicity, No (%)		
	Malay	11(6)
	Chinese	183(91)
	Indian	4(2)
	Others	2(1)
Self-reported hepatitis risk or protective Factor, No (%)		
	Completed questionnaire	176 (100)
	Mother had HBV	53 (30)
	Sibling(s) had HBV	91 (52)
	Living with someone who had hepatitis	95 (55)
	Self-reported vaccination against HBV	6 (3)
	Blood transfusions	21 (12)
	Use of clotting factor or hemodialysis	1 (1)
	Shared use of razor, shaver with others	17 (10)
	Acupuncture or berkam treatment	72 (42)
	Tattoo or other body piercing	43 (25)
	Needle-stick injury	66 (38)
	Multiple sex partners	1 (1)
	IV drug use/ illicit drug use	1 (1)
	Transgender	0 (0)
	Had sex with other man	0 (0)
Linkage to care, No (%)		
	Prior anti-viral treatment	2 (1)
	Post-screening follow-up with any healthcare providers	115 (58)
	Post-screening anti-viral treatment	6 (3)
	Post-screening not contactable	10 (5)
HBV DNA level, No (%)		
	Number of subjects with baseline HBV DNA level measured	108
	Median (IQR) , IU/ml	10,804 (350, 215,664)
	< 2,000 or NOT detectable, No. (%)	40 (37)
	2,000 to <20,000, No. (%)	25 (23)
	20,000 to <100,000, No. (%)	7 (7)
	100,000 to <1,000,000, No. (%)	18 (17)
	>=1,000,000, No. (%)	18 (17)

Table 3: Prevalence of Awareness and Anti-viral treatment among subjects with chronic HBV in Malaysia 2018- 2019

	Awareness		Prior Treatment		Prospective Treatment	
	Number with chronic HBV=200		Number with chronic HBV=200		Number with chronic HBV and HBV DNA>20,000 IU/ml=43	
	Number who were aware of their chronic HBV=33		Number who had received treatment=2		Number who subsequently received treatment=6	
	Prevalence rate %	95% CI	Prevalence rate %	95% CI	Prevalence rate %	95% CI

All	13.1	7.7	18.5	0.7%	0	1.6	15.6	0	31.2
<i>By Age</i>									
20-39 years	7.5	0	15.8	0	-	-	17.9	0	41.1
40-54 years	23.9	14.7	33.1	1.3	0	3.8	0	-	-
>=55 years	13.6	5.7	21.5	1.5	0	4.3	28.8	3.9	53.7
<i>By Gender</i>									
Male	14.1	6.3	21.9	0.7	0	2.0	5.6	0	12.4
Female	11.9	4.6	19.3	0.1	0	1.9	25.8	0	54.8
<i>By Age-Gender</i>									
Male 20-39 years	9.1	0	21.1	0	-	-	0	-	-
40-54 years	28.2	14.1	42.3	2.5	0	7.5	0	-	-
>=55 years	9.5	0.6	18.4	0	-	-	27.3	0.9	54.6
Female 20-39 years	5.9	0	17.1	0	-	-	28.5	0	62.0
40-54 years	19.5	8.1	31.0	0	-	-	0	-	-
>=55 years	17.6	4.8	30.4	2.9	0	8.6	33.3	0	88.9

Discussion

HBV awareness and treatment rates

Chronic HBV is endemic in the Asia-Pacific region, though this has declined in many countries since the advent of universal vaccination of newborn [1]. However there remains a large population of adults who were born before universal vaccination were introduced in the 1990s. These adults bear the huge burden of liver cirrhosis and HCC attributable to HBV in the region; HCC ranked among the top 5 commonest cause of cancer deaths in all East and SE Asian countries without exception [17].

Nevertheless, the cascade of care, awareness and treatment of chronic HBV at the population level are surprisingly understudied in Asia. In fact, we have difficulty finding such studies beside the well-known US National Health Nutrition Examination Survey (NHANES) which has included questions on awareness of HBV only since 2013 [18,19]. Estimating HBV awareness and treatment is challenging in populations with HBV prevalence <2.5% (which is most countries in the world). The NHANES had required a rolling samples of 11,488 subjects over 4 years to identify 68 subjects with HBV of which 22 were aware and 7 treated [18]. Similarly, our survey has a sample size of 10,450 subjects to find 200 subjects with HBV, 33 were aware and 2 treated. Large scale sero-surveys have been conducted in Asia (where many countries have HBV prevalence >5%), notably in China, Korea and Mongolia [20-25]. For unknown reason, they have not reported HBV awareness and treatment rates. Sero-survey cannot determine HBV DNA guided prospective treatment rates.

The Polaris Observatory Collaborators' study [26] have published modelled estimates of HBV awareness and treatment rates for all Asian countries in 2016. Japan, Korea and Taiwan had apparently very high awareness rates of 72%, 83% and 64% respectively. Malaysia was reported to have an awareness rate of 9% and treatment rate 5%, while in this study, the rates are 13.1% and 0.7% respectively. Despite the high percentage of self-reported intra-family HBV infection in this study population, it is concerning to find the low level of HBV awareness. We postulate that this is

likely due to multiple factors in the study population and the healthcare system serving them, which warrant further study. HBV awareness and screening especially amongst women of child bearing age will help prevent mother-to-child transmission which is a vital component in HBV elimination program.

Prospective treatment rate among patients with HBV DNA >20,000 IU/ml, however is higher at 15.6% likely driven by the availability of low-cost generic Tenofovir disoproxil fumarate, which was the only anti-viral drug prescribed to all treated patients in this study. Even in the US, the awareness and prior treatment rates as determined in the NHANES survey were only 32% and 28% respectively [18]. Notwithstanding, these estimates point to the huge gap between current our health system performance and the WHO proposed targets of 90% diagnosis rate and 80% treatment rates required to eliminate HBV [11].

Cascade of care

The low awareness, follow-up and treatment rates highlighted huge gaps in the “cascade of care” for chronic HBV. We discuss how these gaps could be closed in our healthcare setting.

- Access to HBV DNA testing to guide treatment. Only 2 screen- positive subjects had prior HBV DNA levels measured, a test which is still prohibitively costly to most patients in Malaysia. We need low-cost test, alongside a low-cost HBV treatment like generic anti-viral which drove the higher prospective treatment rate observed in this study.
- Adequately resourced and prepared local health services to deliver HBV chronic care. In Malaysia, patients with chronic HBV have hitherto been managed by specialist Hepatologists and Gastroenterologists, the supply of whom is very limited. For example, Pahang, which screened the most subjects in this campaign, has a population of 1.6 million, but only one Gastroenterologist in the public hospital and 2 in private, all are located faraway in the capital city Kuantan. This represents a bottle-neck in the cascade of care which would lead to delays in HBV follow up. In line with current WHO guideline [14], we will need to mobilize the local primary care workforce where the campaign is conducted to deliver the medical care locally for patients with uncomplicated chronic HBV.
- Non-adherence. Only 54% of screen-positive subjects who were offered free HBV DNA had come forward to be tested. And only 58% of subjects with chronic HBV had remained on follow-up with a healthcare provider despite repeated calls and reminders. Likewise, there is likely non-adherence on the part of healthcare providers [27] though this study was not designed to address this issue. Non-adherence is clearly a significant cause of failure in the linkage to care. There is room for improvement in the design and responsiveness of our health services to the needs of patients with chronic disease like HBV [28]. Similarly, we need to begin to address patients’ ignorance about HBV and the stigmatization associated with HBV, and other social and/or cultural barriers to patients seeking care [29,30,31], though again this study was not designed to address these issues.

Study limitations

Our study has several limitations. First, the study subjects were not a probability sample and are not representative of the population. Hence, there were more female and older subjects than in the general population, and Chinese and Pahang residents were over-represented as a result of the conduct of the campaign through local NGOs,

most of which were faith or ethnic based organizations in Pahang. Post-stratification was required to adjust the sampling weight to reflect the age, sex and ethnicity distribution of Malaysia. Second, subjects known to have hepatitis may be more or less willing to participate in screening. This source of bias applies to probability sample too; such subject may be more or less willing to consent to be tested in a sampling survey. The risk of this bias however is lessened in our study by pooling the data from numerous (109) screening events or venues conducted in numerous rural and urban locations spread over a wide geographical region. Third, the determination of awareness and treatment were based on self-report by patient, as is usual in all sample surveys. In our study however, instead of just accepting a Yes/No response to survey questions on awareness and treatment at face value, we had required corroborative information on the circumstances and details on names of provider/treatment and test results before accepting a "Yes" response as indicating awareness or treatment.

References

1. Wong MCS, Huang JLW, George J, Huang J, Leung C, Eslam M, Chan HLY, Ng SC. The changing epidemiology of liver diseases in the Asia-Pacific region. *Nat Rev Gastroenterology Hepatol* 2019; 16: 57–73
2. Lim ZZ, Teo JS, Tan A C, Lim TO. Prevalence of Chronic Hepatitis B and C in Malaysia- results from a community-based screening campaign. Preprint at medRxiv <https://medrxiv.org/cgi/content/short/2020.04.30.20085944v1> (2020).
3. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. *J Hepatol*. 2008;48(2):335-352. doi:10.1016/j.jhep.2007.11.011
4. Pazgan-Simon M, Simon KA, Jarowicz E, Rotter K, Szymanek-Pasternak A, Zuwała-Jagiełło J. Hepatitis B virus treatment in hepatocellular carcinoma patients prolongs survival and reduces the risk of cancer recurrence. *Clin Exp Hepatol*. 2018;4(3):210-216. doi:10.5114/ceh.2018.78127
5. Global Burden of Disease Study 2010 (GBD2010). GBD Profile Malaysia. Available from <http://www.healthmetricsandevaluation.org/gbd/country-profiles>
6. Ferlay J, Colombet M, Soerjomataram I et al. Global and Regional Estimates of the Incidence and Mortality for 38 Cancers: GLOBOCAN 2018. Lyon: International Agency for Research on Cancer/World Health Organization; 2018.
7. Norsa'adah B, Nurhazalini-Zayani CG. Epidemiology and survival of hepatocellular carcinoma in north-east Peninsular Malaysia. *Asian Pac J Cancer Prev* 2013 Nov;14(11):6955-6959.
8. Chen VL, Yeh ML, Le AK, et al. Anti-viral therapy is associated with improved survival but is underutilised in patients with hepatitis B virus-related hepatocellular carcinoma: real-world east and west experience. *Aliment Pharmacol Ther*. 2018;48(1):44-54. doi:10.1111/apt.14801
9. Toy M. Appendix A: population health impact and cost-effectiveness of chronic hepatitis B diagnosis, care, and treatment in the United States. In: Strom BL, Buckley GJ, eds. *A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report*. National Academies Press; 2017:203-234.
10. WHO. Global Health Sector Strategies for viral hepatitis 2016–21. 2016. <http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en>
11. World Health Organization. Global hepatitis report, 2017. Geneva, Switzerland: World Health Organization; 2017.

12. Hepatitis Free Pahang Malaysia. Available from <https://hepatitisfreemsia.org.my/>
13. Muhammad Radzi AH, Tan SS, Rosmawati M, Fauziah J, Senamjit K, Azlida CA, Ghazali AK, Wong HS, Rafidah A, Mohd Ramli S, Mamun AM, Zaki M, Lim TO, for the Hepatitis Study Group*. Hepatitis Screening and Treatment campaign in Malaysia- Validation of low cost Point of Care screening tests and Nucleic Acid Tests for Hepatitis B and C. *Euroasian Journal of Hepato-Gastroenterology* 2018; 8:101-107
14. WHO. Guidelines for the prevention, care and treatment of persons with hepatitis B infection. Geneva: WHO; 2015
<http://www.who.int/hepatitis/publications/hepatitis-b-guidelines/en/>
15. Sarin, S. K. *et al.* Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. *Hepatol. Int.* **10**, 1–98 (2015).
16. Kessler RC, Little RJA, Groves RM. Advances in strategies for minimizing and adjusting for survey nonresponse. *Epidemiologic Reviews* 1995;17:192-204
17. Global Burden of Disease Liver Cancer Collaboration. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level Results From the Global Burden of Disease Study 2015. *JAMA Oncol.* 2017;3(12):1683-1691. doi:10.1001/jamaoncol.2017.3055
18. Zhou K, Terrault NA. Gaps in Viral Hepatitis Awareness in the United States in a Population-based Study. *Clinical Gastroenterology and Hepatology* 2020;18:188–195
19. Kim HS, Yang JD, El-Serag HB, Kanwal F. Awareness of chronic viral hepatitis in the United States: an update from the National Health and Nutrition Examination Survey. *J Viral Hepat.* 2019;26(5):596-602. doi:10.1111/jvh.13060
20. Cui, F. *et al.* Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China. *Emerg. Infect. Dis.* **23**, 765–772 (2017)
21. Xia, G.-L. *et al.* Prevalence of hepatitis B and C virus infections in the general Chinese population. Results from a nationwide cross-sectional seroepidemiologic study of hepatitis A, B, C, D, and E virus infections in China, 1992. *Int. Hepatol. Commun.* **5**, 62–73 (1996).
22. Liang, X. *et al.* Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination. *Vaccine* **27**, 6550–6557 (2009).
23. Recent trends in hepatitis B virus infection in the general Korean population. *Korean J Intern Med.* 2013 Jul;28(4):413-9. doi: 10.3904/kjim.2013.28.4.413
24. Lee, H., Lee, H., Cho, Y., Oh, K. & Ki, M. Changes in seroprevalence of hepatitis B surface antigen and epidemiologic characteristics in the Republic of Korea, 1998–2013. *Epidemiol. Health* **37**, e2015055 (2015)
25. Dashdorj, N., Dashtseren, B., Bold, B. & Yagaanbuyant, D. Epidemiological study of prevalence and risk factors for HBV among apparently healthy Mongolians. *J. Viral Hepatitis* **21**, 21–48 (2014).
26. The Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. *Lancet Gastroenterol Hepatol* 2018; published online March 26.
[http://dx.doi.org/10.1016/S2468-1253\(18\)30056-6](http://dx.doi.org/10.1016/S2468-1253(18)30056-6).
27. Nguyen VH, Le AK, Trinh HN, *et al.* Poor adherence to guidelines for treatment of chronic hepatitis B virus infection at primary care and referral practices. *Clin Gastroenterol Hepatol.* 2019;17(5):957-967.e7. doi:10.1016/j.cgh.2018.10.012
28. Low WHH, Seet W, Ramli AS, Ng KK *et al.* Community-based cardiovascular Risk Factors Intervention Strategies (CORFIS) in managing hypertension: A pragmatic non-randomised controlled trial. *Med J Malaysia* 2013; 68: 129-135

29. Cotler SJ, Cotler S, Xie H, Luc BJ, Layden TJ, Wong SS. Characterizing hepatitis B stigma in Chinese immigrants. *J Viral Hepat* 2012;19:147–52.
30. Li D, Tang T, Patterson M, Ho M, Heathcote J, Shah H. The impact of hepatitis B knowledge and stigma on screening in Canadian Chinese persons. *Can J Gastroenterol* 2012;26:597–602.
31. Yoo GJ, Fang T, Zola J, Dariotis WM. Destigmatizing hepatitis B in the Asian American community: Lessons learned from the San Francisco Hep B Free Campaign. *J Cancer Educ* 2012;27:138–44.

List of abbreviations

CI	Confidence interval
HBV	Hepatitis B virus
HCC	Hepatocellular carcinoma
HCV	Hepatitis C virus
HFBM	Hepatitis Free Pahang Malaysia
MOH	Ministry of Health Malaysia
NGO	Non-Governmental Organizations
NHANES	National Health Nutrition Examination Survey, US
POCT	Point of Care Tests
SD	Standard deviation
WHO	World Health Organization
YLL	Years of life lost

Declarations

Ethics approval and Consent

The Ministry of Health's (MOH) Medical and Research Ethics Committee approved the study. All subjects who participated in the screening campaign gave written informed consent

Consent for Publication

Not applicable. The manuscript does not report on any individual participant's data in any form (images, videos, voice recordings etc).

Availability of data and material

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request

Competing interest

None of the authors have any conflict of interest with respect to this research work

Funding

This study is funded by the Hepatitis Free Pahang Malaysia.

Author's contributions

TSS, RM, GKL, LYY, LWH contributed to the subject matter expertise. They also contributed to the writing of the manuscript. LTO, LZZ, TJS, TAC conceived the idea behind this study and contributed to the study design, survey conduct, data analysis and interpretation and report writing. All authors read and approved the final manuscript.

Acknowledgement

The authors would like to extend their sincere gratitude and appreciation to all the staff and volunteers of Hepatitis Free Pahang Malaysia for their efforts in conducting the screening campaign. We also wish to thank all those whose names are not mentioned here who render their excellent service especially during the data collection.